Mocellin Simone, Mandruzzato Susanna, Bronte Vincenzo, Lise Mario, Nitti Donato
Department of Oncological and Surgical Sciences, University of Padova, Italy.
Lancet Oncol. 2004 Nov;5(11):681-9. doi: 10.1016/S1470-2045(04)01610-9.
Active specific immunotherapy holds great potential in the search for new therapeutic approaches for patients with cancer. Much preclinical and clinical evidence has shown that the immune system can be polarised against malignant cells by several vaccination strategies. Although no anticancer vaccine can be recommended outside clinical trials at present, tumour response and immunological findings in animals and humans should prompt researchers to investigate further the potential of this biotherapy. We summarise strategies for cancer vaccines so far implemented in the clinical setting, report the results of more than 200 clinical trials published over the past two decades, and discuss insights into preclinical tumour immunology that might aid the design of the next generation of cancer vaccines.
主动特异性免疫疗法在为癌症患者寻找新的治疗方法方面具有巨大潜力。大量临床前和临床证据表明，通过多种疫苗接种策略可使免疫系统针对恶性细胞发生极化。尽管目前在临床试验之外尚无抗癌疫苗可被推荐，但动物和人类的肿瘤反应及免疫学发现应促使研究人员进一步探究这种生物疗法的潜力。我们总结了目前在临床环境中实施的癌症疫苗策略，报告了过去二十年发表的200多项临床试验结果，并讨论了对临床前肿瘤免疫学的见解，这些见解可能有助于设计下一代癌症疫苗。
